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1. INTRODUCTION {#gcc22481-sec-0001}
===============

Tumor suppressor genes (TSGs) play a major role in the carcinogenic process by controlling cell growth and apoptosis, inhibiting the formation of tumors. Mutations in TSGs inactivate their inhibitory function, thereby contributing to the carcinogenic process. Proto‐oncogenes likewise are involved in cell growth; when mutated, these oncogenes (OGs) promote cancer through proliferation of cells. Unlike TSGs which require a double hit to inactivate the gene, mutations to OGs are dominant with one copy of the gene needing to be mutated to promote cancer. Several TSGs have been linked to the colorectal cancer (CRC) carcinogenic process, with the adenomatous polyposis coli gene (*APC*) and *TP53* being two of the most commonly mutated TSGs in CRC.[1](#gcc22481-bib-0001){ref-type="ref"} Important OGs in CRC include the RAS genes (ie, *KRAS*, *HRAS*, and *NRAS)*, *BRAF, AKT1*, *EGFR*, *PIK3CA*, *MYC*, and *JAK*. Several of these oncogenes, including *KRAS*, *BRAF*, *MYC*, and *PIK3CA* have been shown to be mutated and/or have altered expression in colorectal cancer (CRC).[2](#gcc22481-bib-0002){ref-type="ref"}, [3](#gcc22481-bib-0003){ref-type="ref"}, [4](#gcc22481-bib-0004){ref-type="ref"} Genetic variation in the *JAK* genes also has been reported as increasing risk of developing CRC.[5](#gcc22481-bib-0005){ref-type="ref"} A balance of TSG function and regulation of OGs is needed to control cell growth.

MiRNAs are small, nonprotein‐coding RNA molecules involved in the regulation of gene expression either by post‐transcriptionally suppressing mRNA translation or by causing mRNA degradation.[6](#gcc22481-bib-0006){ref-type="ref"}, [7](#gcc22481-bib-0007){ref-type="ref"}, [8](#gcc22481-bib-0008){ref-type="ref"}, [9](#gcc22481-bib-0009){ref-type="ref"}, [10](#gcc22481-bib-0010){ref-type="ref"}, [11](#gcc22481-bib-0011){ref-type="ref"} While the function and importance of miRNAs in the carcinogenic process is not completely understood, it is thought that they help regulate cell proliferation and apoptosis and through the loss or gain‐of‐function attributed to them, are likely part of the elaborate cellular pathways regulated by TSG and OGs.[12](#gcc22481-bib-0012){ref-type="ref"}, [13](#gcc22481-bib-0013){ref-type="ref"} MiRNA expression is frequently either down‐regulated or up‐regulated in CRC tissue when compared to normal mucosa,[14](#gcc22481-bib-0014){ref-type="ref"}, [15](#gcc22481-bib-0015){ref-type="ref"} supporting their relevance to neoplasia. Several miRNAs, including miR‐21, miR‐203, miR‐155, miR‐455--3p, and the miR‐17--92 cluster interact with TSGs and OGs to influence cancer processes.[13](#gcc22481-bib-0013){ref-type="ref"}, [16](#gcc22481-bib-0016){ref-type="ref"}, [17](#gcc22481-bib-0017){ref-type="ref"}, [18](#gcc22481-bib-0018){ref-type="ref"}, [19](#gcc22481-bib-0019){ref-type="ref"}, [20](#gcc22481-bib-0020){ref-type="ref"} Groups of miRNAs, such as oncomiR1, are commonly up‐regulated in tumor tissue; in turn these miRNAs along with *MYC* regulate expression of cell cycle transcription factor gene *ESF1*.[12](#gcc22481-bib-0012){ref-type="ref"}, [21](#gcc22481-bib-0021){ref-type="ref"} MiRNAs have been cited as being "critical effectors of several canonical oncogenic and tumor suppressor pathways".[22](#gcc22481-bib-0022){ref-type="ref"}

In this study we examine associations between gene expression of 74 TSGs and 59 OGs that have been previously identified as being associated with cancer[23](#gcc22481-bib-0023){ref-type="ref"} with miRNA expression levels. It is possible that, in addition to mutation, TSG and OG expression is indicative of dysregulated pathways involved in carcinogenesis and not mutated TSGs or OGs. We evaluate TSGs and OGs with a fold change (FC) between paired tumor and normal tissue ≥1.5 or ≤0.67 with miRNAs to have more meaningful levels of expression differences. We believe that insight into the co‐regulator roles of TSG, OG, and miRNAs can further our understanding of the carcinogenic process.

2. PATIENTS AND METHODS {#gcc22481-sec-0002}
=======================

2.1. Study participants {#gcc22481-sec-0003}
-----------------------

Study participants come from two population‐based case‐control studies that included all incident colon and rectal cancer between 30 and 79 years of age in Utah or were members of Kaiser Permanente Medical Care Program (KPMCP) in Northern California. Participants were non‐Hispanic white, Hispanic, or black for the colon cancer study; Asian race was included in the rectal cancer study.[24](#gcc22481-bib-0024){ref-type="ref"}, [25](#gcc22481-bib-0025){ref-type="ref"} Case diagnosis was verified by tumor registry data as a first primary adenocarcinoma of the colon and were diagnosed between October 1991 and September 1994 and for the rectal study were diagnosed between May 1997 and May 2001. Detailed study methods have been described.[15](#gcc22481-bib-0015){ref-type="ref"} The Institutional Review Boards at the University of Utah and at KPMCP approved the study.

2.2. RNA processing {#gcc22481-sec-0004}
-------------------

Formalin‐fixed paraffin embedded tissue from the initial biopsy or surgery was used to extract RNA. RNA was extracted, isolated and purified as previously described[26](#gcc22481-bib-0026){ref-type="ref"} from carcinoma tissue and adjacent normal mucosa.

2.3. mRNA: RNA‐Seq sequencing library preparation and data processing {#gcc22481-sec-0005}
---------------------------------------------------------------------

Total RNA from 245 colorectal carcinoma and normal mucosa pairs was chosen for sequencing based on availability of RNA and high quality miRNA data; 217 pairs passed quality control (QC) and are used in these analyses. RNA library construction was done with the Illumina TruSeq Stranded Total RNA Sample Preparation Kit with Ribo‐Zero (Illumina, San Diego, California). The samples were then fragmented and primed for cDNA synthesis, adapters were then ligated onto the cDNA, and the resulting samples were then amplified using PCR; the amplified library was then purified using Agencount AMPure XP beads (Beckman Coulter, Indianapolis, Indiana). A more detailed description of the methods can be found in our previous work.[27](#gcc22481-bib-0027){ref-type="ref"} Illumina TruSeq v3 single read flow cell and a 50 cycle single‐read sequence run was performed on an Illumina HiSeq instrument. Reads were aligned to a sequence database containing the human genome (build GRCh37/hg19, February 2009 from [genome.ucsc.edu](http://genome.ucsc.edu)) and alignment was performed using novoalign v2.08.01. Total gene counts were calculated for each exon and UTR of the genes using a list of gene coordinates obtained from <http://genome.ucsc.edu>. We disregarded genes that were not expressed in our RNA‐Seq data or for which the expression was missing for the majority of samples.[27](#gcc22481-bib-0027){ref-type="ref"} We focused on expression of 74 TSGs and 59 OGs previously identified as being associated with cancer[23](#gcc22481-bib-0023){ref-type="ref"} (Supporting Information Table 1).

2.4. miRNA {#gcc22481-sec-0006}
----------

The Agilent Human miRNA Microarray V19.0 was used (Agilent, St Clara, California). Data were required to pass stringent QC parameters established by Agilent that included tests for excessive background fluorescence, excessive variation among probe sequence replicates on the array, and measures of the total gene signal on the array to assess low signal. Samples failing to meet quality standards were re‐labeled, hybridized to arrays, and re‐scanned. If a sample failed QC assessment a second time, the sample was excluded from analysis. The repeatability associated with this microarray was extremely high (*r* = 0.98),[15](#gcc22481-bib-0015){ref-type="ref"} comparison of miRNA expression levels obtained from the Agilent microarray to those obtained from qPCR had an agreement of 100% in terms of directionality of findings and the FCs were almost identical.[14](#gcc22481-bib-0014){ref-type="ref"} To normalize differences in miRNA expression that could be attributed to the array, amount of RNA, location on array, or factors that could erroneously influence miRNA expression levels, total gene signal was normalized by multiplying each sample by a scaling factor which was the median of the 75th percentiles of all the samples divided by the individual 75th percentile of each sample.[28](#gcc22481-bib-0028){ref-type="ref"}

2.5. Statistical methods {#gcc22481-sec-0007}
------------------------

DESeq2 was used to identify TSGs and OGs that had a significant difference in expression between individual paired colorectal carcinoma and normal mucosa adjusting for age and sex. The Bioconductor package DESeq2, written for the *R* statistical programming environment, assumes the RNA‐Seq counts are distributed according to negative binomial distributions.[29](#gcc22481-bib-0029){ref-type="ref"} It utilizes generalized linear modeling to test individual null hypotheses of zero log2 FCs between tumor and normal categories (ie, no differential expression) for each TSG and OG and it employs both an independent‐filtering method and the Benjamini and Hochberg[30](#gcc22481-bib-0030){ref-type="ref"} procedure to improve power and control the false discovery rate (FDR). In identifying genes with significant differential expression, an FDR adjusted *P* value of 0.05 was used. We report the average DESeq2‐adjusted gene expression levels among individuals in the tumor and normal mucosa categories and include FC calculations associated with these genes. FC also was calculated as the ratio of a gene\'s mean expression among individuals in the tumor to its mean expression among normal; a FC greater than one indicates a positive differential expression (ie, up‐regulated) while a FC between zero and one indicates a negative differential expression (ie, down‐regulated).

We focus on those TSGs and OGs with FC of ≥1.5 or ≤0.67 for analysis with miRNAs to potentially have differences that were more biologically significant. There are 814 miRNAs expressed in greater than 20% of normal colorectal mucosa that were analyzed; differential expression was calculated as the expression in the carcinoma tissue minus the expression in the normal mucosa within each subject. In these analyses, we fit a least squares linear regression model to the reads per kilobase of transcript per million mapped reads (RPKMs) differential expression levels and miRNA differential expression levels. *P* values were generated using the bootstrap method by creating a distribution of 10,000 F statistics derived by resampling the residuals from the null hypothesis model of no association between miRNA and TSG or miRNA and OG differential expression using the boot package in R. Linear models were adjusted for age and sex. Multiplicity adjustments for gene/miRNA associations were made at the gene level using the FDR by Benjamini and Hochberg.[30](#gcc22481-bib-0030){ref-type="ref"} We transformed the RPKMs and miRNA to standard normal to standardize the regression slopes to compare the results across TSGs and OGs. We considered overall CRC as well as microsatellite unstable (MSI) and stable (MSS) tumors since MSI tumors are usually hyper‐mutated.[31](#gcc22481-bib-0031){ref-type="ref"}

3. RESULTS {#gcc22481-sec-0008}
==========

The majority of cases were colon cancer (77.9%) while 22.1% were diagnosed with rectal cancer (Table [1](#gcc22481-tbl-0001){ref-type="table-wrap"}). The population consisted of 54.4% men, 74.2% non‐Hispanic white, and a mean age of 64.8 years. Based on the hot‐spot locations sequenced for *TP53* 47.5% were mutated, 31.8% had a *KRAS* mutation, 10.1% had a *BRAF* mutation, 20.7% were CIMP high, and 13.4% were MSI.

###### 

Description of study population

                                         *N*    (%)
  ----------------- -------------------- ------ ------
  Site                                          
                    Colon                169    77.9
                    Rectal               48     22.1
  Sex                                           
                    Male                 118    54.4
                    Female               99     45.6
  Age                                           
                    Mean (SD)            64.8   10.1
  Race                                          
                    Non‐Hispanic White   161    74.2
                    Hispanic             14     6.5
                    Non‐Hispanic Black   8      3.7
                    Unknown              34     15.7
  AJCC Stage                                    
                    1                    58     27.1
                    2                    61     28.5
                    3                    72     33.6
                    4                    23     10.8
  Tumor phenotype                               
                    *TP53* mutated       103    47.5
                    *KRAS* mutated       69     31.8
                    *BRAF*‐mutated       21     10.1
                    CIMP High            45     20.7
                    MSI                  29     13.4
  Vital status                                  
                    Dead                 92     42.6
                    Alive                124    57.4

Of the 74 TSGs evaluated, six (*PAX5, IZKF1, GATA3, PRDM1, TET2*, and *CYLD*) were significantly down‐regulated with a FC of ≤0.67 after adjustment for multiple comparisons (Table [2](#gcc22481-tbl-0002){ref-type="table-wrap"}). Five additional TSGs, (*ATM*, *SMAD4*, *APC*, *KDM6A*, and *FBXW7*), were significantly down‐regulated when a FC of 0.75 or less was applied. Ten mRNAs were up‐regulated with a FC ≥1.5 and an FDR of \<0.05. These 10 TSGs were *FAM123B, RB1, TP53, RUNX1, MSH2, BRCA1, BRCA2*, *SOX9, NPM1*, and *RNF43*. *ASXL1, CDKN2A, MSH6*, and *PHF6* had a FC between 1.45 and 1.5. Other TSGs (*N* = 30) were statistically significantly up‐ or down‐regulated after adjustment for multiple comparisons but with FCs closer to 1.0. Looking separately at MSI and MSS tumors showed some slight differences in magnitude of differential expression of TSGs. For MSI tumors (Supporting Information Table 2), three additional genes, (*MLH1, PTCH1,* and *CEBPA*) were significantly down‐regulated and *MSH6* was significantly up‐regulated (FCs: 0.48, 0.56, 0.40, and 1.51, respectively). For MSS tumors, *PHF6* and *ASXL1* (FCs: 1.57 and 1.50, respectively) were significantly up‐regulated; APC was only slightly more downregulated in MSS tumors (0.72 vs. 0.74 overall) (Supporting information Table 3).

###### 

Tumor suppressor genes (TSG) differentially expressed in colorectal cancer

              Mean expression                           
  ----------- ----------------- -------- ------ ------- ------------
  *PAX5*      7.39              31.89    0.23   −2.11   2.33E--44
  *IKZF1*     39.20             102.32   0.38   −1.38   2.63E--66
  *GATA3*     3.82              7.97     0.48   −1.06   2.77E--07
  *PRDM1*     81.55             132.11   0.62   −0.70   4.15E--30
  *TET2*      145.62            232.97   0.63   −0.68   4.65E--68
  *CYLD*      88.07             133.85   0.66   −0.60   1.41E--34
  *ATM*       266.98            362.05   0.74   −0.44   2.34E--25
  *SMAD4*     102.47            138.70   0.74   −0.44   3.59E--27
  *APC*       115.05            155.21   0.74   −0.43   3.59E--27
  *KDM6A*     91.78             123.80   0.74   −0.43   3.03E--23
  *FBXW7*     53.86             71.75    0.75   −0.41   2.80E--14
  *GATA1*     0.70              0.93     0.75   −0.41   0.91
  *NCOR1*     444.29            589.76   0.75   −0.41   0.95
  *ACVR1B*    104.62            129.79   0.81   −0.31   3.11E--12
  *TSC1*      127.06            157.25   0.81   −0.31   0.99
  *PTEN*      143.07            174.86   0.82   −0.29   1.77E--13
  *SMAD2*     186.11            223.36   0.83   −0.26   3.46E--16
  *CDKN2C*    6.18              7.37     0.84   −0.25   0.44
  *EP300*     326.24            387.06   0.84   −0.25   0.99
  *MLH1*      37.54             43.60    0.86   −0.22   7.42E--03
  *ARID2*     181.30            206.27   0.88   −0.19   0.99
  *MAP2K4*    35.32             39.81    0.89   −0.17   0.02
  *ARID1A*    259.52            291.77   0.89   −0.17   0.99
  *MAP3K1*    83.61             93.65    0.89   −0.16   1.49E--04
  *MLL3*      707.40            789.64   0.90   −0.16   0.99
  *PTCH1*     149.31            165.98   0.90   −0.15   6.70E--03
  *BAP1*      84.45             91.67    0.92   −0.12   7.17E--03
  *CIC*       102.02            110.61   0.92   −0.12   0.06
  *SETD2*     292.98            313.68   0.93   −0.10   0.99
  *CREBBP*    294.85            313.68   0.94   −0.09   0.99
  *TNFAIP3*   119.32            124.18   0.96   −0.06   0.20
  *MLL2*      646.44            672.13   0.96   −0.06   0.99
  *ARID1B*    246.14            255.23   0.96   −0.05   0.99
  *B2M*       835.45            850.74   0.98   −0.03   0.99
  *NOTCH2*    289.31            286.58   1.01   0.01    0.99
  *STK11*     74.67             72.44    1.03   0.04    0.35
  *PIK3R1*    174.64            168.38   1.04   0.05    0.99
  *FUBP1*     205.57            196.55   1.05   0.06    0.99
  *PBRM1*     176.09            166.12   1.06   0.08    0.99
  *MEN1*      40.36             37.10    1.09   0.12    3.82E--03
  *CDC73*     79.29             72.84    1.09   0.12    0.08
  *SOCS1*     5.44              4.95     1.10   0.14    0.99
  *HNF1A*     70.70             63.81    1.11   0.15    4.57E--04
  *NF2*       91.86             81.64    1.13   0.17    1.98E--03
  *SMARCB1*   42.07             37.28    1.13   0.17    1.62E--03
  *KDM5C*     260.17            226.43   1.15   0.20    0.99
  *CDH1*      591.70            512.34   1.15   0.21    5.32E--05
  *AXIN1*     113.21            95.38    1.19   0.25    6.70E--06
  *CEBPA*     59.18             49.57    1.19   0.26    0.08
  *CASP8*     80.57             67.38    1.20   0.26    4.44E--07
  *BCOR*      103.15            85.65    1.20   0.27    5.11E--11
  *VHL*       102.14            84.59    1.21   0.27    1.77E--13
  *TRAF7*     131.07            105.65   1.24   0.31    2.49E--10
  *DAXX*      39.23             31.55    1.24   0.31    1.28E--08
  *NF1*       418.54            329.17   1.27   0.35    0.99
  *SMARCA4*   259.78            193.93   1.34   0.42    0.95
  *ATRX*      316.31            230.97   1.37   0.45    0.95
  *NOTCH1*    333.76            243.66   1.37   0.45    7.54E--19
  *STAG2*     323.20            235.41   1.37   0.46    8.89E--27
  *ASXL1*     243.04            168.14   1.45   0.53    6.68E--27
  *CDKN2A*    9.33              6.41     1.46   0.54    5.25E--03
  *MSH6*      83.43             56.02    1.49   0.57    1.07E--27
  *PHF6*      78.99             52.85    1.49   0.58    1.02E--27
  *FAM123B*   52.60             31.53    1.67   0.74    2.54E--26
  *RB1*       118.98            69.86    1.70   0.77    1.82E--39
  *TP53*      116.26            67.95    1.71   0.77    1.73E--23
  *RUNX1*     285.66            155.93   1.83   0.87    4.94E--62
  *MSH2*      54.53             29.60    1.84   0.88    2.30E--38
  *WT1*       2.36              1.22     1.93   0.95    0.67
  *BRCA1*     97.57             41.36    2.36   1.24    1.92E--56
  *BRCA2*     95.40             39.33    2.43   1.28    7.21E--56
  *SOX9*      297.74            122.07   2.44   1.29    4.90E--96
  *NPM1*      242.28            90.51    2.68   1.42    2.76E--100
  *RNF43*     641.08            179.11   3.58   1.84    3.06E--116

Further evaluation of the 22 TSGs that were significantly differentially expressed with a FC ≥1.5 or ≤0.67, either for overall CRC or MSI and MSS‐specific tumors, showed that 13 TSGs were associated with miRNA expression (Table [3](#gcc22481-tbl-0003){ref-type="table-wrap"}). Several miRNAs were associated with multiple TSGs. For instance, miR‐150--5p was associated with five TSGs (*PRDM1, CYLD, GATA3, IKZF1*, and *PAX5*), miR‐15a‐5p with four TSGs (*RNF43, SOX9*, *RB1,* and *ASXL1*), miR‐17--5p with six TSGs (*BRCA1, RNF43, SOX9, BRCA2*, *RB1,* and *ASXL1*), miR‐203a with three TSGs (*RNF43, SOX9,* and *IKZF1*), miR‐20a‐5p with five TSGs (*RNF43, SOX9, BRCA2*, *RB1,* and *ASXL1*), miR‐29a‐3p with four TSGs (*RNF43, SOX9, RB1,* and *ASXL1*), miR‐425--5p with four TSGs (*BRCA1, RNF43, SOX9,* and *ASXL1*), and miR‐92a‐3p with seven TSGs (*BRCA1, RNF43, SOX9, BRCA2, RB1, ASXL1,* and *FAM123B*). Interestingly, all of the TSGs associated with miR‐150--5p were down‐regulated as was miR‐150--5p. Likewise, all TSGs associated with miR‐17--5p, miR‐20a‐5p, miR‐29a‐3p, miR‐425--5p, and miR‐92a‐3p were up‐regulated as were the miRNAs themselves.

###### 

Significantly differentially expressed tumor suppressor genes (TSG) with ≥1.5 or ≤0.67 fold change and miRNA associations

  TSG         TSG fold change   miRNA              Tumor mean   Normal mean   miRNA fold change   Beta between miRNA and TSG expression   FDR *P* value
  ----------- ----------------- ------------------ ------------ ------------- ------------------- --------------------------------------- ---------------
  *BRCA1*     2.36              hsa‐miR‐17--5p     61.04        16.38         3.73                0.27                                    0.041
                                hsa‐miR‐425--5p    11.76        6.97          1.69                0.26                                    0.027
                                hsa‐miR‐92a‐3p     121.60       41.18         2.95                0.28                                    0.027
  *PRDM1*     0.62              hsa‐miR‐146b‐5p    4.46         2.67          1.67                0.28                                    0.023
                                hsa‐miR‐150--5p    14.90        39.17         0.38                0.28                                    0.016
                                hsa‐miR‐195--5p    3.59         12.18         0.29                0.23                                    0.041
                                hsa‐miR‐199b‐5p    4.69         1.53          3.07                0.26                                    0.016
                                hsa‐miR‐650        4.51         16.60         0.27                0.30                                    0.016
  *CYLD*      0.66              hsa‐miR‐150--5p    14.90        39.17         0.38                0.32                                    0.020
  *GATA3*     0.48              hsa‐miR‐150--5p    14.90        39.17         0.38                0.34                                    0.041
  *RNF43*     3.58              hsa‐miR‐106b‐5p    15.90        5.19          3.06                0.22                                    0.017
                                hsa‐miR‐1291       5.52         3.67          1.51                0.27                                    0.004
                                hsa‐miR‐130b‐3p    8.74         4.89          1.79                0.23                                    0.013
                                hsa‐miR‐151a‐3p    5.15         1.56          3.31                0.21                                    0.018
                                hsa‐miR‐15a‐5p     7.69         5.07          1.52                0.23                                    0.012
                                hsa‐miR‐17--5p     61.04        16.38         3.73                0.29                                    0.004
                                hsa‐miR‐196b‐5p    17.89        5.53          3.24                0.19                                    0.035
                                hsa‐miR‐199b‐5p    4.69         1.53          3.07                0.18                                    0.049
                                hsa‐miR‐19b‐3p     29.80        10.42         2.86                0.21                                    0.015
                                hsa‐miR‐203a       12.52        3.70          3.38                0.17                                    0.047
                                hsa‐miR‐20a‐5p     70.78        17.61         4.02                0.30                                    0.004
                                hsa‐miR‐20b‐5p     17.65        3.30          5.35                0.25                                    0.010
                                hsa‐miR‐21--5p     463.11       167.37        2.77                0.18                                    0.042
                                hsa‐miR‐221--3p    13.53        4.12          3.28                0.18                                    0.035
                                hsa‐miR‐23a‐3p     174.68       87.53         2.00                0.19                                    0.028
                                hsa‐miR‐27a‐3p     56.26        23.29         2.42                0.21                                    0.017
                                hsa‐miR‐29a‐3p     110.29       51.04         2.16                0.26                                    0.007
                                hsa‐miR‐29b‐3p     24.31        9.83          2.47                0.22                                    0.015
                                hsa‐miR‐3191--3p   0.90         1.97          0.45                −0.18                                   0.042
                                hsa‐miR‐361--5p    11.62        6.20          1.87                0.20                                    0.022
                                hsa‐miR‐3651       58.66        25.92         2.26                0.24                                    0.007
                                hsa‐miR‐378d       0.45         2.43          0.18                −0.19                                   0.033
                                hsa‐miR‐3976       2.97         1.24          2.39                0.18                                    0.038
                                hsa‐miR‐424--3p    39.81        25.37         1.57                0.26                                    0.007
                                hsa‐miR‐425--5p    11.76        6.97          1.69                0.26                                    0.009
                                hsa‐miR‐501--3p    7.07         2.95          2.39                0.25                                    0.007
                                hsa‐miR‐513c‐3p    2.15         3.50          0.62                −0.17                                   0.049
                                hsa‐miR‐5685       1.28         2.78          0.46                −0.19                                   0.036
                                hsa‐miR‐663b       65.50        32.21         2.03                0.21                                    0.018
                                hsa‐miR‐92a‐3p     121.60       41.18         2.95                0.33                                    0.004
                                hsa‐miR‐93--5p     41.72        15.20         2.74                0.21                                    0.017
  *SOX9*      2.44              hsa‐miR‐1207--3p   1.18         1.93          0.61                −0.23                                   0.026
                                hsa‐miR‐15a‐5p     7.69         5.07          1.52                0.23                                    0.026
                                hsa‐miR‐17--5p     61.04        16.38         3.73                0.24                                    0.026
                                hsa‐miR‐1915--5p   1.04         1.77          0.59                −0.22                                   0.027
                                hsa‐miR‐203a       12.52        3.70          3.38                0.21                                    0.038
                                hsa‐miR‐20a‐5p     70.78        17.61         4.02                0.23                                    0.025
                                hsa‐miR‐21--5p     463.11       167.37        2.77                0.21                                    0.039
                                hsa‐miR‐27a‐3p     56.26        23.29         2.42                0.21                                    0.035
                                hsa‐miR‐29a‐3p     110.29       51.04         2.16                0.23                                    0.024
                                hsa‐miR‐3651       58.66        25.92         2.26                0.20                                    0.038
                                hsa‐miR‐425--5p    11.76        6.97          1.69                0.20                                    0.039
                                hsa‐miR‐532--3p    2.74         1.67          1.64                0.20                                    0.050
                                hsa‐miR‐92a‐3p     121.60       41.18         2.95                0.25                                    0.018
                                hsa‐miR‐93--5p     41.72        15.20         2.74                0.21                                    0.035
  *BRCA2*     2.43              hsa‐miR‐17--5p     61.04        16.38         3.73                0.29                                    0.020
                                hsa‐miR‐20a‐5p     70.78        17.61         4.02                0.28                                    0.020
                                hsa‐miR‐92a‐3p     121.60       41.18         2.95                0.36                                    0.020
  *RB1*       1.70              hsa‐miR‐1207--3p   1.18         1.93          0.61                −0.22                                   0.049
                                hsa‐miR‐15a‐5p     7.69         5.07          1.52                0.23                                    0.048
                                hsa‐miR‐17--5p     61.04        16.38         3.73                0.22                                    0.049
                                hsa‐miR‐1915--5p   1.04         1.77          0.59                −0.24                                   0.046
                                hsa‐miR‐20a‐5p     70.78        17.61         4.02                0.22                                    0.049
                                hsa‐miR‐29a‐3p     110.29       51.04         2.16                0.24                                    0.046
                                hsa‐miR‐92a‐3p     121.60       41.18         2.95                0.31                                    0.027
  *TET2*      0.63              hsa‐miR‐375        20.50        54.53         0.38                0.32                                    0.041
                                hsa‐miR‐663a       374.83       234.91        1.60                −0.31                                   0.041
  *ASXL1*     1.50              hsa‐miR‐106b‐5p    15.90        5.19          3.06                0.21                                    0.044
                                hsa‐miR‐15a‐5p     7.69         5.07          1.52                0.25                                    0.028
                                hsa‐miR‐17--5p     61.04        16.38         3.73                0.26                                    0.021
                                hsa‐miR‐20a‐5p     70.78        17.61         4.02                0.27                                    0.016
                                hsa‐miR‐25--3p     30.05        12.78         2.35                0.23                                    0.030
                                hsa‐miR‐29a‐3p     110.29       51.04         2.16                0.23                                    0.046
                                hsa‐miR‐361--5p    11.62        6.20          1.87                0.22                                    0.038
                                hsa‐miR‐424--3p    39.81        25.37         1.57                0.21                                    0.022
                                hsa‐miR‐425--5p    11.76        6.97          1.69                0.24                                    0.026
                                hsa‐miR‐92a‐3p     121.60       41.18         2.95                0.35                                    0.010
                                hsa‐miR‐93--5p     41.72        15.20         2.74                0.22                                    0.038
  *FAM123B*   1.67              hsa‐miR‐330--3p    2.81         5.59          0.50                −0.23                                   0.033
                                hsa‐miR‐378d       0.45         2.43          0.18                −0.22                                   0.042
                                hsa‐miR‐501--3p    7.07         2.95          2.39                0.21                                    0.045
                                hsa‐miR‐532--3p    2.74         1.67          1.64                0.23                                    0.034
                                hsa‐miR‐92a‐3p     121.60       41.18         2.95                0.27                                    0.024
  *IKZF1*     0.38              hsa‐miR‐146a‐5p    10.73        6.93          1.55                0.28                                    0.031
                                hsa‐miR‐150--5p    14.90        39.17         0.38                0.47                                    0.012
                                hsa‐miR‐203a       12.52        3.70          3.38                −0.25                                   0.012
                                hsa‐miR‐497--5p    1.77         7.12          0.25                0.24                                    0.041
                                hsa‐miR‐650        4.51         16.60         0.27                0.36                                    0.012
  *PAX5*      0.23              hsa‐miR‐150--5p    14.90        39.17         0.38                0.37                                    0.041

Evaluating CRC overall, 14 OGs were significantly down‐regulated when a FC of ≤0.67 was applied (Table [4](#gcc22481-tbl-0004){ref-type="table-wrap"}). Additionally, eight OGs were significantly down‐regulated but with FC values above this level. Seven OGs were up‐regulated with FCs ≥1.5. An additional seven OGs were significantly up‐regulated with FCs ranging from 1.1 to 1.38. Evaluation of tumors that had MSI specifically showed that three genes, (*FLT3, CARD11*, and *ALK*) were significantly down‐regulated (FCs 0.30, 0.33, and 0.32, respectively) and two additional genes were significantly up‐regulated (*IDH2* FC 1.69 and *HRAS* FC 1.85) (Supporting information Table 4). All other up‐ and down‐regulated genes were similar except for *AR* which had a FC of 0.80 (adjusted *P* = 0.04) compared to CRC overall where *AR* had a FC of 0.6 (adjusted *P* = 2.03E--13). For MSS tumors, *CTNNB1*, which encodes β‐catenin, was significantly up‐regulated (Supporting information Table 5). *BRAF* and *KRAS* were not significantly differentially expressed in our data.

###### 

Oncogenes (OG) differentially expressed in colorectal cancer

                Mean expression                           
  ------------- ----------------- -------- ------ ------- ------------
  *KLF4*        75.45             324.72   0.23   −2.11   1.13E--149
  *ALK*         1.68              6.64     0.25   −1.98   0.18
  *BCL2*        26.44             73.52    0.36   −1.48   7.06E--72
  *SETBP1*      40.32             106.95   0.38   −1.41   4.48E--62
  *FGFR2*       31.67             81.23    0.39   −1.36   6.00E--49
  *TSHR*        4.69              11.60    0.40   −1.31   8.41E--27
  *FLT3*        2.55              5.92     0.43   −1.22   0.49
  *MPL*         1.14              2.49     0.46   −1.13   1.95E--04
  *KIT*         18.19             39.18    0.46   −1.11   2.11E--35
  *PDGFRA*      98.04             195.40   0.50   −0.99   1.14E--38
  *GNA11*       40.13             79.90    0.50   −0.99   8.87E--55
  *GATA2*       10.61             20.64    0.51   −0.96   2.59E--17
  *FGFR3*       44.59             85.93    0.52   −0.95   2.50E--35
  *AR*          48.01             80.52    0.60   −0.75   2.03E--13
  *RET*         5.62              9.04     0.62   −0.69   0.77
  *CSF1R*       37.88             60.49    0.63   −0.68   4.02E--18
  *JAK3*        53.42             82.50    0.65   −0.63   5.11E--12
  *GNAQ*        139.24            197.36   0.71   −0.50   1.10E--34
  *EGFR*        190.64            256.70   0.74   −0.43   0.91
  *MDM4*        315.31            417.46   0.76   −0.40   0.91
  *SPOP*        57.78             75.20    0.77   −0.38   6.69E--13
  *U2AF1*       189.37            239.72   0.79   −0.34   0.92
  *ERBB2*       246.04            307.97   0.80   −0.32   2.67E--11
  *JAK2*        56.21             69.14    0.81   −0.30   1.41E--12
  *ABL1*        181.26            212.55   0.85   −0.23   0.96
  *MYD88*       69.45             79.03    0.88   −0.19   9.96E--04
  *SF3B1*       480.83            537.63   0.89   −0.16   0.98
  *KRAS*        127.67            139.54   0.91   −0.13   1.32E--06
  *JAK1*        217.29            234.31   0.93   −0.11   0.98
  *AKT1*        170.13            183.07   0.93   −0.11   0.98
  *H3F3A*       53.68             57.59    0.93   −0.10   0.02
  *BRAF*        60.66             63.92    0.95   −0.08   0.01
  *NFE2L2*      142.43            144.43   0.99   −0.02   0.99
  *PPP2R1A*     158.30            153.95   1.03   0.04    0.99
  *DNMT3A*      78.42             75.20    1.04   0.06    0.47
  *MED12*       137.54            130.81   1.05   0.07    0.55
  *CARD11*      25.77             24.37    1.06   0.08    0.98
  *NCOA3*       209.78            196.81   1.07   0.09    0.47
  *SMO*         15.49             14.50    1.07   0.10    0.98
  *CBL*         132.65            120.52   1.10   0.14    0.01
  *MAP2K1*      35.34             32.02    1.10   0.14    0.07
  *SRSF2*       166.29            139.17   1.19   0.26    0.96
  *MDM2*        277.54            231.90   1.20   0.26    0.04
  *IDH1*        92.17             75.94    1.21   0.28    1.21E--05
  *GNAS*        632.89            490.95   1.29   0.37    0.92
  *NRAS*        117.35            90.21    1.30   0.38    1.57E--09
  *MYCL1*       22.87             17.34    1.32   0.40    1.44E--04
  *IDH2*        102.70            75.07    1.37   0.45    2.82E--11
  *HRAS*        21.15             15.30    1.38   0.47    7.11E--08
  *CTNNB1*      630.77            417.97   1.51   0.59    0.81
  *DNMT1*       140.56            87.48    1.61   0.68    1.52E--29
  *MYCN*        3.22              1.91     1.69   0.76    0.77
  *EZH2*        64.20             37.25    1.72   0.79    4.31E--30
  *NKX2*--*1*   1.94              1.09     1.78   0.83    0.81
  *PTPN11*      249.19            136.54   1.82   0.87    2.13E--72
  *SKP2*        54.13             28.28    1.91   0.94    3.63E--36
  *CCND1*       345.41            145.50   2.37   1.25    1.09E--102
  *MET*         352.22            103.44   3.40   1.77    1.31E--128
  *MYC*         207.70            60.72    3.42   1.77    6.94E--89

Of the 27 OGs that showed statistically significant FCs of ≥1.5 or ≤0.67, 12 were associated with miRNA differential expression (Table [5](#gcc22481-tbl-0005){ref-type="table-wrap"}). *BCL2* was associated with 11 miRNAs, *CCND1* with six, *CSF1R* with two, *CTNNB1* with one, *FGFR2* with three, *JAK3* with five, *KLF4* with five, *MET* with 40, *MYC* with 14, *PDGFRA* with two, *PTPN11* with 13, and *SETBP1* with 10. Several miRNAs were associated with 2 OGs: let‐7i‐5p, miR‐106b‐5p, miR‐1207--3p, miR‐1246, miR‐133b, miR‐146b‐5p, miR‐1915--5p, miR‐19b‐3p, miR‐195--5p, miR‐20b‐5p, miR‐21--5p, miR‐23a‐3p, miR‐29b‐3p, miR‐30a‐5p, miR‐330--3p, miR‐425--5p, miR‐501--3p, and miR‐6515--5p. MiR‐27a‐3p, miR‐29a‐3p, miR‐3651, miR‐497--5p, miR‐650, miR‐663b, miR‐92a‐3p were associated with three OGs and miR‐145--5p, miR‐150--5p, miR‐17--5p, miR‐203a, miR‐20a‐5p, miR‐375, miR‐663a, and miR‐93--5p were associated with four OGs. All but two OGs that were differentially expressed in CRC had a mixture of up‐ and down‐regulated miRNAs associated with them. *CTNNB1,* which was up‐regulated, was associated with one miRNA (miR‐1915--5p) that was also up‐regulated; *PDGFRA* which was down‐regulated was associated with two miRNAs (miR‐145--3p and miR‐497--5p) which were also down‐regulated.

###### 

Differentially expressed oncogenes (OG) associated with miRNA differential expression

  Oncogene   Tumor mean   Normal mean   Fold change   MiRNA              Tumor mean   Normal mean   Fold change   Beta    Raw *P* value   FDR *P* value
  ---------- ------------ ------------- ------------- ------------------ ------------ ------------- ------------- ------- --------------- ---------------
  *FGFR2*    31.67        81.23         0.39          hsa‐miR‐145--5p    132.97       223.14        0.60          0.27    0.0002          0.04
                                                      hsa‐miR‐375        20.50        54.53         0.38          0.27    0.0002          0.04
                                                      hsa‐miR‐663a       374.83       234.91        1.60          −0.26   0.0002          0.04
  *JAK3*     53.42        82.50         0.65          hsa‐let‐7i‐5p      62.16        39.97         1.56          0.23    0.001           0.04
                                                      hsa‐miR‐146a‐5p    10.73        6.93          1.55          0.27    \<.0001         0.01
                                                      hsa‐miR‐146b‐5p    4.46         2.67          1.67          0.29    \<.0001         0.01
                                                      hsa‐miR‐150--5p    14.90        39.17         0.38          0.41    \<.0001         0.01
                                                      hsa‐miR‐650        4.51         16.60         0.27          0.33    \<.0001         0.01
  *MET*      352.22       103.44        3.40          hsa‐let‐7i‐5p      62.16        39.97         1.56          0.20    0.004           0.03
                                                      hsa‐miR‐106b‐5p    15.90        5.19          3.06          0.24    0.001           0.01
                                                      hsa‐miR‐1207--3p   1.18         1.93          0.61          −0.22   0.002           0.02
                                                      hsa‐miR‐1246       629.21       412.81        1.52          0.24    0.0002          0.01
                                                      hsa‐miR‐1258       1.82         3.73          0.49          −0.23   0.001           0.01
                                                      hsa‐miR‐1291       5.52         3.67          1.51          0.19    0.007           0.04
                                                      hsa‐miR‐151a‐3p    5.15         1.56          3.31          0.21    0.003           0.02
                                                      hsa‐miR‐17--5p     61.04        16.38         3.73          0.27    \<.0001         0.004
                                                      hsa‐miR‐1915--5p   1.04         1.77          0.59          −0.24   0.001           0.01
                                                      hsa‐miR‐19b‐3p     29.80        10.42         2.86          0.23    0.002           0.02
                                                      hsa‐miR‐203a       12.52        3.70          3.38          0.28    \<.0001         0.004
                                                      hsa‐miR‐20a‐5p     70.78        17.61         4.02          0.29    \<.0001         0.004
                                                      hsa‐miR‐20b‐5p     17.65        3.30          5.35          0.19    0.007           0.04
                                                      hsa‐miR‐2117       1.50         4.09          0.37          −0.20   0.003           0.02
                                                      hsa‐miR‐21--5p     463.11       167.37        2.77          0.30    \<.0001         0.004
                                                      hsa‐miR‐221--3p    13.53        4.12          3.28          0.26    0.0002          0.01
                                                      hsa‐miR‐222--3p    19.45        11.08         1.76          0.27    0.0003          0.01
                                                      hsa‐miR‐23a‐3p     174.68       87.53         2.00          0.31    \<.0001         0.004
                                                      hsa‐miR‐24--3p     106.75       62.39         1.71          0.28    \<.0001         0.004
                                                      hsa‐miR‐25--3p     30.05        12.78         2.35          0.20    0.006           0.04
                                                      hsa‐miR‐27a‐3p     56.26        23.29         2.42          0.34    \<.0001         0.004
                                                      hsa‐miR‐29a‐3p     110.29       51.04         2.16          0.34    \<.0001         0.004
                                                      hsa‐miR‐29b‐3p     24.31        9.83          2.47          0.30    \<.0001         0.004
                                                      hsa‐miR‐3181       2.11         3.71          0.57          −0.23   0.001           0.01
                                                      hsa‐miR‐324--5p    5.20         2.27          2.29          0.21    0.003           0.03
                                                      hsa‐miR‐330--3p    2.81         5.59          0.50          −0.22   0.001           0.02
                                                      hsa‐miR‐34a‐5p     25.15        12.32         2.04          0.19    0.005           0.04
                                                      hsa‐miR‐3651       58.66        25.92         2.26          0.32    \<.0001         0.004
                                                      hsa‐miR‐424--3p    39.81        25.37         1.57          0.18    0.008           0.05
                                                      hsa‐miR‐425--5p    11.76        6.97          1.69          0.22    0.002           0.02
                                                      hsa‐miR‐4458       3.33         5.56          0.60          −0.23   0.001           0.01
                                                      hsa‐miR‐4469       1.11         2.41          0.46          −0.24   0.001           0.01
                                                      hsa‐miR‐4520b‐3p   1.96         3.17          0.62          −0.22   0.001           0.01
                                                      hsa‐miR‐501--3p    7.07         2.95          2.39          0.20    0.004           0.03
                                                      hsa‐miR‐513c‐3p    2.15         3.50          0.62          −0.21   0.004           0.03
                                                      hsa‐miR‐5685       1.28         2.78          0.46          −0.21   0.003           0.02
                                                      hsa‐miR‐6071       0.97         1.70          0.57          −0.20   0.004           0.03
                                                      hsa‐miR‐6515--5p   1.20         4.41          0.27          −0.24   0.001           0.01
                                                      hsa‐miR‐92a‐3p     121.60       41.18         2.95          0.32    \<.0001         0.004
                                                      hsa‐miR‐93--5p     41.72        15.20         2.74          0.28    \<.0001         0.004
  *CCND1*    345.41       145.50        2.37          hsa‐miR‐17--5p     61.04        16.38         3.73          0.27    0.0002          0.03
                                                      hsa‐miR‐203a       12.52        3.70          3.38          0.28    \<.0001         0.03
                                                      hsa‐miR‐20a‐5p     70.78        17.61         4.02          0.27    \<.0001         0.03
                                                      hsa‐miR‐21--5p     463.11       167.37        2.77          0.25    0.0004          0.04
                                                      hsa‐miR‐27a‐3p     56.26        23.29         2.42          0.28    0.0003          0.03
                                                      hsa‐miR‐93--5p     41.72        15.20         2.74          0.26    0.0003          0.03
  *PDGFRA*   98.04        195.40        0.50          hsa‐miR‐145--5p    132.97       223.14        0.60          0.28    0.0002          0.04
                                                      hsa‐miR‐497--5p    1.77         7.12          0.25          0.24    0.0004          0.05
  *KLF4*     75.45        324.72        0.23          hsa‐miR‐375        20.50        54.53         0.38          0.39    \<.0001         0.03
                                                      hsa‐miR‐6515--5p   1.20         4.41          0.27          0.27    0.0003          0.03
                                                      hsa‐miR‐663a       374.83       234.91        1.60          −0.37   \<.0001         0.03
                                                      hsa‐miR‐663b       65.50        32.21         2.03          −0.31   \<.0001         0.03
                                                      hsa‐miR‐934        4.36         0.94          4.66          −0.26   0.0002          0.03
  *MYC*      207.70       60.72         3.42          hsa‐miR‐1246       629.21       412.81        1.52          0.23    0.001           0.04
                                                      hsa‐miR‐17--5p     61.04        16.38         3.73          0.35    \<.0001         0.02
                                                      hsa‐miR‐19b‐3p     29.80        10.42         2.86          0.24    0.001           0.04
                                                      hsa‐miR‐203a       12.52        3.70          3.38          0.23    0.001           0.04
                                                      hsa‐miR‐20a‐5p     70.78        17.61         4.02          0.34    \<.0001         0.02
                                                      hsa‐miR‐20b‐5p     17.65        3.30          5.35          0.25    0.001           0.03
                                                      hsa‐miR‐29a‐3p     110.29       51.04         2.16          0.25    0.0003          0.02
                                                      hsa‐miR‐29b‐3p     24.31        9.83          2.47          0.23    0.001           0.04
                                                      hsa‐miR‐330--3p    2.81         5.59          0.50          −0.24   0.001           0.03
                                                      hsa‐miR‐3651       58.66        25.92         2.26          0.29    \<.0001         0.02
                                                      hsa‐miR‐501--3p    7.07         2.95          2.39          0.22    0.001           0.04
                                                      hsa‐miR‐663b       65.50        32.21         2.03          0.25    0.0003          0.02
                                                      hsa‐miR‐92a‐3p     121.60       41.18         2.95          0.35    \<.0001         0.02
                                                      hsa‐miR‐93--5p     41.72        15.20         2.74          0.25    0.0003          0.02
  *SETBP1*   40.32        106.95        0.38          hsa‐miR‐133b       1.71         6.94          0.25          0.30    \<.0001         0.01
                                                      hsa‐miR‐145--5p    132.97       223.14        0.60          0.38    \<.0001         0.01
                                                      hsa‐miR‐150--5p    14.90        39.17         0.38          0.32    \<.0001         0.01
                                                      hsa‐miR‐195--5p    3.59         12.18         0.29          0.29    0.0002          0.01
                                                      hsa‐miR‐30a‐5p     2.38         4.61          0.52          0.28    \<.0001         0.01
                                                      hsa‐miR‐375        20.50        54.53         0.38          0.25    0.0003          0.01
                                                      hsa‐miR‐497--5p    1.77         7.12          0.25          0.31    \<.0001         0.01
                                                      hsa‐miR‐650        4.51         16.60         0.27          0.23    0.001           0.04
                                                      hsa‐miR‐663a       374.83       234.91        1.60          −0.26   0.0003          0.01
                                                      hsa‐miR‐99a‐5p     6.30         3.70          1.71          0.23    0.001           0.04
  *CTNNB1*   690.35       441.80        1.56          hsa‐miR‐1915--5p   1.04         1.77          0.59          −0.28   \<.0001         0.04
  *BCL2*     26.44        73.52         0.36          hsa‐miR‐133b       1.71         6.94          0.25          0.22    0.002           0.04
                                                      hsa‐miR‐145--5p    132.97       223.14        0.60          0.25    \<.0001         0.01
                                                      hsa‐miR‐150--5p    14.90        39.17         0.38          0.38    \<.0001         0.01
                                                      hsa‐miR‐195--5p    3.59         12.18         0.29          0.29    \<.0001         0.01
                                                      hsa‐miR‐30a‐5p     2.38         4.61          0.52          0.26    0.0002          0.01
                                                      hsa‐miR‐375        20.50        54.53         0.38          0.27    \<.0001         0.01
                                                      hsa‐miR‐497--5p    1.77         7.12          0.25          0.32    \<.0001         0.01
                                                      hsa‐miR‐583        6.61         3.22          2.05          −0.22   0.002           0.04
                                                      hsa‐miR‐650        4.51         16.60         0.27          0.30    \<.0001         0.01
                                                      hsa‐miR‐663a       374.83       234.91        1.60          −0.32   \<.0001         0.01
                                                      hsa‐miR‐663b       65.50        32.21         2.03          −0.25   0.001           0.02
  *PTPN11*   249.19       136.54        1.82          hsa‐miR‐106b‐5p    15.90        5.19          3.06          0.23    0.001           0.04
                                                      hsa‐miR‐1207--3p   1.18         1.93          0.61          −0.23   0.001           0.04
                                                      hsa‐miR‐15a‐5p     7.69         5.07          1.52          0.22    0.002           0.05
                                                      hsa‐miR‐17--5p     61.04        16.38         3.73          0.24    0.0004          0.03
                                                      hsa‐miR‐203a       12.52        3.70          3.38          0.22    0.002           0.04
                                                      hsa‐miR‐20a‐5p     70.78        17.61         4.02          0.25    0.001           0.03
                                                      hsa‐miR‐23a‐3p     174.68       87.53         2.00          0.22    0.002           0.05
                                                      hsa‐miR‐27a‐3p     56.26        23.29         2.42          0.24    0.0004          0.03
                                                      hsa‐miR‐29a‐3p     110.29       51.04         2.16          0.24    0.001           0.03
                                                      hsa‐miR‐3651       58.66        25.92         2.26          0.24    0.001           0.03
                                                      hsa‐miR‐425--5p    11.76        6.97          1.69          0.30    \<.0001         0.03
                                                      hsa‐miR‐92a‐3p     121.60       41.18         2.95          0.28    \<.0001         0.03
                                                      hsa‐miR‐93--5p     41.72        15.20         2.74          0.24    0.001           0.03
  *CSF1R*    37.88        60.49         0.63          hsa‐miR‐146b‐5p    4.46         2.67          1.67          0.26    0.0003          0.04
                                                      hsa‐miR‐150--5p    14.90        39.17         0.38          0.29    \<.0001         0.03

4. DISCUSSION {#gcc22481-sec-0009}
=============

Of the 74 TSGs evaluated, 59 were significantly differentially expressed; 22 of these differentially expressed TSGs were more strongly associated with CRC either overall or for MSI and MSS tumors specifically as indicated by a FC ≥1.5 or ≤0.67. Of these 22 TSGs, 13 were up‐regulated in carcinoma tissue compared to paired normal tissue. Evaluation of these 22 TSGs with differential expression of miRNAs showed that 13 TSGs were significantly associated with expression of 44 miRNA. Twenty‐seven OGs were statistically significantly dysregulated when considering higher FC levels. Evaluation of MSI tumors showed that two additional OGs were statistically significantly up‐regulated (*IDH2* FC 1.69 and *HRAS* FC 1.85) and three OGs were down‐regulated (*FLT3* FC 0.30, *CARD11* FC 0.33, and *ALK* FC 0.32). *CTNNB1* was significantly up‐regulated in MSS tumors. Twelve of the 27 OGs significantly differentially expressed were associated with 56 miRNAs. The majority of TSGs/OGs were associated with multiple miRNAs and miRNAs were associated with several TSGs/OGs.

Several factors need to be considered when evaluating TSG and OG differential expression. First, TSG and OG differential expression does not necessarily correlate with TSG and OG mutation. Our data suggest that in known *TP53*‐mutated, *KRAS*‐mutated, and *BRAF*‐mutated samples there were no differences in gene expression between mutated and nonmutated samples (counts adjusted from DESeq2: *TP53*‐mutated vs. not *TP53*‐mutated 136 vs. 144 and TP53 expression in normal tissue of 63; *KRAS*‐mutated 155 vs. not *KRAS*‐mutated 155; *BRAF*‐mutated 75 vs. not *BRAF*‐mutated 70). We further evaluated TP53 expression based on loss of function (LOF) mutations such as frameshift, stop, and insertion/deletions which represented roughly 1/3 of *TP53* mutations. For LOF mutations the mean level of expression was 78.8 while for missense *TP53* mutations it was 153.1. This suggest that LOF mutations reduces expression to a level comparable to the normal level of expression, while TP53 expression is elevated in *TP53*‐missense mutation mutated and non‐TP53‐mutated tumors. *APC,* another TSG, was down‐regulated in our data (FC = 0.74); *APC* mutations are usually stop mutations and frame shifts, which would lead to loss of functional protein and possibly less stable mRNA through nonsense‐mediated RNA decay;[32](#gcc22481-bib-0032){ref-type="ref"}, [33](#gcc22481-bib-0033){ref-type="ref"} these mutations occur in roughly 80% of the CRC cases and could affect gene expression and occurred in 35 of 40 individuals in this dataset for which we had *APC* mutational status. Down‐regulation of *MLH1* would be expected in mismatch repair deficient tumors (as was seen in our data); *MLH1* promoter methylation and subsequent transcriptional silencing is the most common cause of sporadic mismatch repair deficiency.[34](#gcc22481-bib-0034){ref-type="ref"}, [35](#gcc22481-bib-0035){ref-type="ref"}, [36](#gcc22481-bib-0036){ref-type="ref"} In our data, tumors that had *MLH1* methylation had significantly lower levels of MLH1 expression than those that did not have *MLH1* methylation (19.9 vs. 50.0).

Several TSGs, including *TP53*, *RB1*, *BRCA1*, and *BRCA2,* were up‐regulated, possibly in response to cell stress. Others have observed up‐regulated expression of TSGs such as *CDKN2A* (p16) in CRC tumors.[37](#gcc22481-bib-0037){ref-type="ref"} In our data, *CDKN2A* was up‐regulated with a fold change of 1.46. Romagosa and colleagues[37](#gcc22481-bib-0037){ref-type="ref"} offered several explanations for the up‐regulation of *CDKN2A* in cancer. *CDKN2A* is part of a large pathway that includes RB, which is responsible for blocking S phase entry in the cell cycle; if the pathway is not functioning properly then the expected inactivation of cell proliferation may not occur. Romagosa et al.[37](#gcc22481-bib-0037){ref-type="ref"} interpreted their data to indicate that overexpression of *CDKN2A* in conjunction with expression of other genes, such as *COX2*, would impact the role of *RB* in the malignant lesion. Expression of *KRAS* was not significantly altered in our tumor samples although roughly 35% of our samples had a *KRAS* mutation. It has been shown that *KRAS* mutations can dysregulate genes associated with cell cycle and apoptosis,[38](#gcc22481-bib-0038){ref-type="ref"} supporting the hypothesis that mutations in genes can dysregulate pathways that may have clinical relevance to the carcinogenic process.

The gene expression patterns of differentially expressed TSGs and OGs in our data lend themselves to several distinct observations. First, the majority of significantly differentially expressed TSGs were up‐regulated (19 TSG upregulated vs. 13 down‐regulated). The second observed pattern was the unique functions and pathways associated with dysregulated TSGs. Five of the six of the TSGs most strongly down‐regulated were linked to the NFκB‐signaling pathway or immune response (Table [6](#gcc22481-tbl-0006){ref-type="table-wrap"}). For instance, *CYLD* negatively regulates NFκB activation and is involved in other immune response mechanisms.[39](#gcc22481-bib-0039){ref-type="ref"} When TSGs such as *CYLD* are down‐regulated, excessive inflammation occurs and tumorigenic factors can be promoted.[40](#gcc22481-bib-0040){ref-type="ref"} Conversely, TSGs that were up‐regulated were more likely to be involved in cell cycle regulation, apoptosis, and cell growth, possibly as a response to cell stress in early stages of tumorigenesis. Several OGs that were significantly up‐regulated, such as *DNMT1*, *EZH2*, and *IDH2,* are involved in chromatin modification and remodeling; *CCND1* (cyclin D1), *MYC*, and *SPK2* are important regulators of apoptosis, and *MET*, *PTPN11*, and *HRAS* are important signal transducers. Up‐regulation of these OGs could promote cell growth. However, a larger number of OGs were down‐regulated, possibly counteracting the carcinogenic process. These genes include *AR*, *BCL2*, *CSF1R*, *FGFR2*, *FGFR3*, *GATA2*, *GNA11*, *JAK3*, *KIT*, *KLF4*, *PDGFRA*, *SETBP1*, *TSHR*, *FLT3*, *ALK*, and *CARD11*, which mainly function as transcriptional regulators and are involved in regulation of major signaling pathways participating in inflammation or immune response: PI3K/AKT, JAK/STAT, RAS, TGFβ signaling, NFκB signaling, and VEGF signaling.

###### 

Pathways and functions of tumor suppressor genes (TSG) and oncogenes (OG) significantly differentially expressed in colorectal tissue with fold change of ≥1.5 or ≤0.67

  Overall                      Up or down regulated   Major pathway                                                                                                                    Major function
  ---------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Tumor suppressor genes**                                                                                                                                                           
  * BRCA1*                     *Up‐regulated*         DNA damage control                                                                                                               Genome maintenance
  * PRDM1*                     *Down‐regulated*       NFkB‐signaling; B cell development pathways; regulation of TP53 activity                                                         A repressor of beta‐interferon gene expression
  * CYLD*                      *Down‐regulated*       TNF signaling; Immune System; NOD1/2 Signaling; RIG‐1/MDA5 mediated induction of IFN‐alpha/beta pathway; Wnt‐signaling pathway   Ubiquitin‐dependent protein catabolic process; regulation of tumor necrosis factor‐mediated signaling pathway; cell cycle regulation
  * MSH2*                      *Up‐regulated*         DNA damage control; mismatch repair                                                                                              Mismatch repair gene; genome maintenance
  * GATA3*                     *Down‐regulated*       IL‐27 mediated signaling events; NFkB Signaling; IL‐4 Signaling and their effects on immune response                             Regulator of T‐cell Development; Required for the T‐helper 2 differentiation process following immune and inflammatory responses
  * RNF43*                     *Up‐regulated*         Wnt‐signaling                                                                                                                    Inhibits Wnt‐signaling; cell fate
  * SOX9*                      *Up‐regulated*         Wnt‐signaling; cAMP signaling                                                                                                    Normal skeletal development; acts as a transcription factor for other genes; cell survival
  * BRCA2*                     *Up‐regulated*         DNA damage control                                                                                                               Genome maintenance
  * RB1*                       *Up‐regulated*         Cellular senescence                                                                                                              Cell cycle regulator; transcription factor activity
  * TP53*                      *Up‐regulated*         Apoptosis; DNA damage control                                                                                                    Cell survival; DNA repair
  * RUNX1*                     *Up‐regulated*         Transport of glucose and other sugars, bile salts and organic acids; transcriptional misregulation in cancer                     Transcription regulation; regulatory region DNA binding
  * TET2*                      *Down‐regulated*       Activated PKN1 stimulates transcription of AR regulated genes; chromatin modification                                            Methylcytosine dioxygenase activity
  * NPM1*                      *Up‐regulated*         BARD1 signaling; chromosome maintenance; apoptosis                                                                               Nucleic acid binding; cell survival
  * FAM123B (AMER1)*           *Up‐regulated*         Wnt‐signaling                                                                                                                    Regulates transcriptional activity several genes including APC; cell fate
  * IKZF1*                     *Down‐regulated*       NFkB‐signaling; transcription regulation                                                                                         Cell fate
  * PAX5*                      *Down‐regulated*       NFKB‐signaling; C‐MYB transcription factor network                                                                               Transcription factor activity; cell fate
  **MSI only**                                                                                                                                                                         
  * MLH1*                      *Down‐regulated*       DNA damage control; mismatch repair                                                                                              Mismatch repair gene; genome maintenance
  * MSH6*                      *Up‐regulated*         Mismatch repair; DNA damage control                                                                                              Mismatch repair gene; genome maintenance
  * PTCH1*                     *Down‐regulated*       Signaling by GPCR; Hedgehog pathway; PKA signaling                                                                               Protein complex binding; cell fate
  * CEBPA*                     *Down‐regulated*       Adipogenesis; glucose energy metabolism; NF‐KB signaling; PI3K; RAS                                                              Transcription factor activity; cell survival
  **MSS only**                                                                                                                                                                         
  * PHF6*                      *Up‐regulated*         Transcriptional regulation                                                                                                       RNA binding and histone binding; cell fate
  * ASXL1*                     *Up‐regulated*         Chromatin modification                                                                                                           Transcription co‐activator activity; retinoic acid receptor binding; cell fate
  **Oncogenes**                                                                                                                                                                        
  * AR*                        Down                   Transcriptional regulation; regulation of nuclear SMAD2/3 signaling                                                              Regulates gene expression; affects cellular proliferation
  * BCL2*                      Down                   Cell cycle/apoptosis; TGF‐beta pathway; TNFR1 pathway                                                                            Regulates cell death/cell survival
  * CCND1*                     Up                     Cell cycle/apoptosis; Wnt pathway                                                                                                Protein kinase activity; cell fate
  * CSF1R*                     Down                   PI3K; RAS; AKT1 signaling pathway                                                                                                Mediates activation of MAP Kinase; Cell survival; promotes the release of pro‐inflammatory chemokines in response to IL34 and CSF1; promotes cancer cell invasion
  * DNMT1*                     Up                     Chromatin modification                                                                                                           Maintains methylation patterns following DNA replication; epigenetic gene regulation
  * EZH2*                      Up                     Chromatin modification                                                                                                           Involved in maintaining the transcriptional repressive state of genes over successive cell generations; cell development
  * FGFR2*                     Down                   PI3K; RAS; STAT; VEGF signaling pathway                                                                                          Influences cell growth and differentiation; cell proliferation
  * FGFR3*                     Down                   PI3K; RAS; STAT; VEGF signaling pathway                                                                                          Influences cell growth and differentiation; cell proliferation
  * GATA2*                     Down                   NOTCH, TGF‐b; NF‐κB signaling                                                                                                    Transcription factors
  * GNA11*                     Down                   PI3K; RAS; STAT                                                                                                                  Modulators or transducers in various transmembrane signaling
  * JAK3*                      Down                   STAT; RET signaling; NK‐κB signaling                                                                                             Cytokine receptor‐mediated intracellular signal transduction; predominately expressed in immune cells
  * KIT*                       Down                   PI3K; RAS; STAT                                                                                                                  Transmembrane receptor for mast cell growth factor (stem cell growth factor)
  * KLF4*                      Down                   Transcriptional regulation; WNT; stem cell differentiation pathways                                                              Transcription factors
  * MET*                       Up                     PI3K; RAS                                                                                                                        Cell survival, cell migration, and invasion
  * MPL*                       Down                   JAK‐STAT signaling; NF‐κB signaling                                                                                              Transmembrane signaling receptor activity; immune response
  * MYC*                       Up                     Cell cycle/apoptosis; regulation of nuclear SMAD2/3 signaling                                                                    Cell cycle progression, apoptosis, cellular transformation; functions as a transcription factor; activates transcription of growth‐related genes
  * PDGFRA*                    Down                   PI3K; RAS                                                                                                                        Plays a role in organ development, wound healing and tumor progression
  * PTPN11*                    Up                     RAS; interferon gamma signaling; RET signaling                                                                                   Signaling molecules that regulate cell growth, differentiation, mitotic, cycle and oncogenic transformation
  * SETBP1*                    Down                   Chromatin modification; replication                                                                                              DNA replication
  * SKP2*                      Up                     Cell cycle/apoptosis                                                                                                             Protein binding; ubiquitin‐protein transferase activity
  * TSHR*                      Down                   PI3K; MAPK                                                                                                                       Thyroid cell metabolism; cAMP signaling pathway
  **MSI only**                                                                                                                                                                         
  * ALK*                       Down                   PI3K; RAS; MAPK                                                                                                                  Insulin receptor superfamily; cell proliferation induction; drives NF‐κB activation
  * CARD11*                    Down                   Cell cycle/apoptosis; immune response; RET signaling                                                                             Positive regulator of NF‐κB activation;
  * FLT3*                      Down                   PI3K; RAS; STAT                                                                                                                  Involved in apoptosis, cell proliferation and differentiation
  * HRAS*                      Up                     RAS; RET signaling; VEGF signaling                                                                                               Signal transduction pathways
  * IDH2*                      Up                     Chromatin modification; metabolism                                                                                               Involved in intermediary metabolism and energy production\'; NAP
  **MSS only**                                                                                                                                                                         
  * CTNNB1*                    Up                     Wnt‐signaling; APC                                                                                                               Adherens junctions; regulate cell growth and adhesion between cells; transcription factor activity

Increased inflammation, angiogenesis, and decreased immune response are hallmarks of many of the major pathways in which dysregulated TSGs and OGs operate. PI3K (*PIK3CA*) induces the activation of Akt1 (alias *PDK1*) and is recognized as an important regulator of cell proliferation and survival and links to inflammation.[41](#gcc22481-bib-0041){ref-type="ref"} Akt promotes tumorigenesis by inhibiting apoptosis by inactivating *BCL2*, by stabilizing *MYC*, by inducing the degradation of cyclin‐dependent kinase (*CDK1*), or by triggering activity of NFκB signaling.[42](#gcc22481-bib-0042){ref-type="ref"} Cytokine receptors utilize nonreceptor protein tyrosine kinases, such as JAK, to transmit their signals to the signal transducers and activators of transcription (STATs). A functional JAK/STAT pathway is also critical to an effective immune response.[43](#gcc22481-bib-0043){ref-type="ref"} *JAK3* and *JAK2* were down‐regulated in our data; *JAK3* has been shown to be uniquely associated with intestinal epithelial cells. *JAK3* has been shown to interfere with *GATA3*, a TSG that was down‐regulated in our data and is associated with NFκB‐signaling.[43](#gcc22481-bib-0043){ref-type="ref"} Expression of *BCL2,* which is involved in apoptosis, has also been shown to be regulated by the JAK/STAT‐signaling pathway and TGFβ‐signaling;[44](#gcc22481-bib-0044){ref-type="ref"}, [45](#gcc22481-bib-0045){ref-type="ref"} *BCL2* was down‐regulated in our data. Other protein tyrosine kinases, such as *FLT3*, *KIT*, and *EGFR*, are classified as receptor protein kinases. All of these OGs were down‐regulated in our data and are involved in activation of multiple signaling pathways including cell proliferation, immune response, and angiogenesis.[46](#gcc22481-bib-0046){ref-type="ref"}, [47](#gcc22481-bib-0047){ref-type="ref"}, [48](#gcc22481-bib-0048){ref-type="ref"} *FLT3,* part of the VEGF‐signaling pathway, is a key element in angiogenesis and ties into P13K/AKT signaling and requires *STAT3* for effective cell proliferation.[49](#gcc22481-bib-0049){ref-type="ref"}

Because MSI tumors are hyper‐mutated, we thought that it was important to evaluate differential TSG/OG expression for MSI and MSS tumors separately. For the most part, the same genes were over or under‐expressed in these specific tumor phenotypes. However, there was a difference in the FC of expression of several TSGs and OGs between MSI and MSS tumors. As might be expected, the difference in expression for mismatch repair genes in MSI tumors was greater. *MLH1* was strongly down‐regulated while *MSH6* was strongly up‐regulated in MSI tumors. *PTCH1*, involved in Hedgehog pathway and PKA signaling, and *CEBPA*, involved in NFκB‐signaling and PI3K pathways, were down‐regulated in MSI tumors. Two additional TSGs, *PHF6* and *ASXL1,* were strongly up‐regulated in MSS tumors. Both of these genes are involved in transcription regulation and cell fate. Several OGs were significantly associated specifically with MSI tumors. *ALK, CARD11,* and *FLT3* were only significantly down‐regulated in MSI tumors. Two other genes, *HRAS* and *IDH2,* were significantly up‐regulated in overall colorectal tumors (*HRAS* FC 1.38; *IDH2* FC 1.37), but the FCs of these genes in MSI tumors was much stronger (*HRAS* FC 1.85; *IDH2* FC 1.69). These OGs are primarily involved in signal transduction, inflammation, or immune response pathways that include PI3K/AKT, MAPK, RAS, RET, and VEGF signaling.

The exact function of miRNAs is not clearly understood; however, our results indicate that they are part of regulatory networks through both direct and indirect effects on OGs and TSGs. It has been suggested that miRNAs work with OGs and TSGs.[13](#gcc22481-bib-0013){ref-type="ref"} A study in brain cancer has shown that miR‐128 can activate gene expression by repressing nonsense‐mediated RNA decay.[50](#gcc22481-bib-0050){ref-type="ref"} An example of the complexity of signaling and regulation networks is *MYC*, a frequently studied OG in cancer. In our data, *MYC* had a FC of 3.42. *MYC* has been shown to up‐regulate oncomR1, which includes a cluster of six miRNAs, miR‐17--5p, miR‐18a, miR‐19a, miR‐20a, miR19b‐1, and miR‐92.[51](#gcc22481-bib-0051){ref-type="ref"} In our data, these miRNAs, except for miR‐18a and miR‐19a, were up‐regulated and associated with *MYC* up‐regulation. Three of the six miRNAs in miR‐17--92 cluster also have been regulated in conjunction with the TSGs *RBL1, CDKN1A* (p21*), PTEN,* and *APC*.[18](#gcc22481-bib-0018){ref-type="ref"}, [19](#gcc22481-bib-0019){ref-type="ref"}, [22](#gcc22481-bib-0022){ref-type="ref"}

Studies have shown that some miRNAs, such as miR‐16, restrict mediators needed to control inflammatory response; it has been suggested that other miRNAs might also work in similar manner to miR‐16 to destabilize inflammatory response.[52](#gcc22481-bib-0052){ref-type="ref"}, [53](#gcc22481-bib-0053){ref-type="ref"} Studies have shown that miRNAs such as miR‐320a directly target β catenin, a central component of the Wnt‐signaling pathway, to suppress cell proliferation.[54](#gcc22481-bib-0054){ref-type="ref"} Several OGs, including *CTNNB1*, *CCND1*, and *KLF4,* were part of the Wnt‐signaling pathway. In this pathway, associations are stronger for MSS tumor phenotype. Several miRNAs associated with *CCND1*, including miR‐17--5p, miR‐203a, miR‐20a‐5p, miR‐21--5p, miR‐27a‐3p, miR‐93--5p, were also associated with up‐regulated TSGs in the Wnt‐ signaling pathway (ie, *RNF43* and *SOX9*).

Several miRNAs have been associated with the immune system, including miR‐16, miR‐142--3, miR‐150, miR‐125b, miR‐21, miR‐223, miR‐9, miR‐30, miR‐181, miR‐17--92 cluster, and miR‐155.[53](#gcc22481-bib-0053){ref-type="ref"}, [55](#gcc22481-bib-0055){ref-type="ref"} MiR‐150--5p was down‐regulated in our data in conjunction with the five TSGs that were down‐regulated and had immune and inflammation‐related functions. Of these, *PRDM1* was previously cited as being down‐regulated by several miRNAs including miR‐30, miR‐9 and miR‐125b.[53](#gcc22481-bib-0053){ref-type="ref"} Five of the six TSGs that were down‐regulated, were associated with miR‐150--5p which is also down‐regulated. All of these TSGs, including *GATA3,* were associated with inflammation‐related pathways such as the NFκB‐signaling pathway, suggesting a role in inflammation regulation. However, all of the OGs associated with miR‐150--5p, namely *SETBP1*, *JAK3*, *BCL2*, and *CSF1R,* were also down‐regulated. These OGs also are involved in inflammation‐related pathways. MiR‐150--5p expression may be reduced in response to less TSG protein production, as a reduction in target availability is related to miRNA down‐regulation, resulting from dissociation of the miRNA‐inducing silencing complex, which leaves miRNAs vulnerable to degradation.[56](#gcc22481-bib-0056){ref-type="ref"}

Some of the miRNAs and TSGs were inversely associated. Examples of these associations were miR‐3191--3p (down‐regulated) and *RNF43* (up‐regulated); miR‐378d (down) and *RNF43* and *FAM123B* (up); miR‐1207--3p and 1915--5p (down) and *SOX9* and *RB1* (up); miR‐663a (up) and *TET2* (down); and miR‐146a‐3p and miR‐203‐a (up) and *IKZF1* (down). However, often both the miRNA and TSG were either simultaneously up‐regulated or down‐regulated, which may imply indirect associations between the miRNA and the TSG or could be the result of modifying effects of either lifestyle or genetic factors.[57](#gcc22481-bib-0057){ref-type="ref"}, [58](#gcc22481-bib-0058){ref-type="ref"}, [59](#gcc22481-bib-0059){ref-type="ref"}, [60](#gcc22481-bib-0060){ref-type="ref"}, [61](#gcc22481-bib-0061){ref-type="ref"}, [62](#gcc22481-bib-0062){ref-type="ref"} Additionally, several TSGs also are transcription factors (TF), and as such may directly up‐regulate miRNA transcription and co‐regulate biological functions with miRNAs through feedback and feed forward loops.[63](#gcc22481-bib-0063){ref-type="ref"}, [64](#gcc22481-bib-0064){ref-type="ref"}, [65](#gcc22481-bib-0065){ref-type="ref"} In feedback loops, regulatory paths through TF and miRNAs can have either the same effect or opposite effects on target genes as well as on each other.[64](#gcc22481-bib-0064){ref-type="ref"} In feed‐forward loops, a regulator such as a TF or miRNA, regulates the expression of a target via a direct as well as an indirect path. It has been suggested that regulatory paths involving miRNAs and TF are prevalent mechanisms of gene expression.[64](#gcc22481-bib-0064){ref-type="ref"} *PAX5*, *IKZF1*, *GATA3*, and *PRDM1*, all TFs that were down‐regulated TSGs in our CRC data, were simultaneously associated with down‐regulated miRNAs. Studies have previously shown that *PAX5*, *PRDM1*, and *IKZF11* share a regulatory network with miR‐150--5p via feed forward loops.[63](#gcc22481-bib-0063){ref-type="ref"} Similar mechanisms may be operating for other OGs in conjunction with miRNAs.

The study is uniquely suited to examine associations between differential TSG/OG expressions in CRC. Our large sample size offers power to determine significant associations; our use of RNA‐Seq data as well as the Agilent miRNA platform allows us to take a discovery approach which enables us to better illuminate pathways of interest. We looked at TSG/OGs that had higher levels of differential expression, although the cut‐points of ≥1.5 or ≤0.67 FC was arbitrary. Additionally, we were able to evaluate TSGs/OGs expression with miRNA expression. While we are able to identify numerous associations it is often difficult to determine if associations are direct or indirect in complex biological pathways. Other study strengths include our paired carcinoma and normal mucosa expression data. Having individuals paired data allows us to control for potential confounding effects of genetic and lifestyle factors that could influence both gene and miRNA expression.[57](#gcc22481-bib-0057){ref-type="ref"}, [58](#gcc22481-bib-0058){ref-type="ref"}, [59](#gcc22481-bib-0059){ref-type="ref"}, [62](#gcc22481-bib-0062){ref-type="ref"} Similarly, our tumor phenotype data allowed us to investigate differences in gene expression associated with MSS and MSI tumors, as well as *TP53*‐mutated, *KRAS*‐mutated, and *BRAF*‐mutated tumors. Our expression data have been shown to have both high repeatability as well as reliability when compared to other ascertainment methods.[14](#gcc22481-bib-0014){ref-type="ref"}, [15](#gcc22481-bib-0015){ref-type="ref"} We encourage others with similar data to undertake replication of our findings in population‐based studies as well as laboratory‐based studies to better test the proposed functionality.

In summary, our data suggest that several TSG and OGs expression is dysregulated in CRC, suggesting a cellular response to stress. Our data suggest that miRNAs most likely have both direct and indirect effects on TSG and OGs. It is possible that they work as intermediary regulators between OGs and TSGs, and help to balance up‐ and down‐regulation of these genes that can lead to, as well as counter, cell proliferation and apoptosis, which is the hallmark of carcinogenic processes.

Supporting information
======================

###### 

Supporting Information Tables.

###### 

Click here for additional data file.

The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official view of the National Cancer Institute. We acknowledge Sandra Edwards for data oversight and study management, and Michael Hoffman and Erica Wolff for miRNA analysis. We acknowledge Dr. Bette Caan and the staff at the Kaiser Permanente Medical Research Program for sample and data collection. Supporting Information accompanies the paper on Genes, Chromosomes, and Cancer Website
